These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27856510)

  • 1. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
    Proschmann R; Baldow C; Rothe T; Suttorp M; Thiede C; Tauer JT; Müller MC; Hochhaus A; Roeder I; Glauche I
    Haematologica; 2017 Feb; 102(2):e39-e42. PubMed ID: 27856510
    [No Abstract]   [Full Text] [Related]  

  • 2. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
    Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
    Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
    Cai Y; Liu C; Guo Y; Chen X; Zhang L; Chen Y; Zou Y; Yang W; Zhu X
    Int J Hematol; 2021 Mar; 113(3):413-421. PubMed ID: 33386594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
    Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
    Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
    [No Abstract]   [Full Text] [Related]  

  • 7. Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion.
    Crampe M; Garry J; Langabeer SE; Murphy PT
    Hematol Oncol Stem Cell Ther; 2016 Dec; 9(4):168-169. PubMed ID: 27352262
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: a single-institution experience.
    Moschovi M; Adamaki M; Athanasiadou A; Divane A; Karytianou A; Tourkantoni N
    Leuk Lymphoma; 2015; 56(8):2460-2. PubMed ID: 25641431
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
    Marin D
    J Clin Oncol; 2014 Feb; 32(5):379-84. PubMed ID: 24419129
    [No Abstract]   [Full Text] [Related]  

  • 12. The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
    Zhang H; Liang Z; Hu Y; Wang X; Wang B; Huang H
    Leuk Lymphoma; 2018 Dec; 59(12):3018-3019. PubMed ID: 29616854
    [No Abstract]   [Full Text] [Related]  

  • 13. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
    Cortes J; Rea D; Lipton JH
    Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
    Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
    Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
    [No Abstract]   [Full Text] [Related]  

  • 17. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
    Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
    Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
    Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilotinib in the treatment of chronic myeloid leukemia.
    Sacha T; Saglio G
    Future Oncol; 2019 Mar; 15(9):953-965. PubMed ID: 30547682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of inducible NOS is indispensable for the antiproliferative and proapoptotic effect of imatinib in BCR-ABL positive cells.
    Singh AK; Awasthi D; Dubey M; Nagarkoti S; Chandra T; Barthwal MK; Tripathi AK; Dikshit M
    J Leukoc Biol; 2021 Nov; 110(5):853-866. PubMed ID: 33527482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.